Ondansetron-LENS, 2 mg/ml 4 ml

Ondansetron is a highly selective 5NT3 receptor antagonist. The mechanism of nausea and vomiting suppression is not exactly known. Radiation therapy and cytostatic drugs may release serotonin (5NT) in the small intestine, causing the gag reflex through activation of 5NT3 receptors and excitation of vagus nerve afferent fiber endings.

Indications

– prevention and treatment of nausea and vomiting caused by cytostatic chemotherapy and radiation therapy in adults.
– prevention and treatment of nausea and vomiting caused by cytostatic chemotherapy in children from 6 months.
– prevention and treatment of postoperative nausea and vomiting in adults and children from 1 month.

Pharmacological effect

Ondansetron is a highly selective 5HT3 receptor antagonist. The mechanism of suppression of nausea and vomiting is not precisely known. During radiation therapy and the use of cytotoxic drugs, it is possible to release serotonin (5HT) in the small intestine, causing the gag reflex through activation of 5HT3 receptors and excitation of the endings of the afferent fibers of the vagus nerve.

Special instructions

In patients who have received previous treatment with other selective 5HT3 receptor antagonists, accompanied by hypersensitivity reactions, hypersensitivity reactions are also possible when using Ondansetron-Lance.

Active ingredient

Ondansetron

Composition

1 ml of solution contains:

Contraindications

– hypersensitivity to ondansetron or other components of the drug;

– simultaneous use of ondansetron with apomorphine;

– pregnancy and breastfeeding;

– children under 6 months of age for the indication “Prevention and treatment of nausea and vomiting caused by cytostatic chemotherapy”;

– children up to 1 month of age according to the indication “Prevention and treatment of postoperative nausea and vomiting in children”;

– congenital long QT interval syndrome.

Caution: Caution should be exercised when used in patients with hypersensitivity reactions to other 5HT3 receptor antagonists; in patients with 5 disorders of heart rhythm and conduction; in patients receiving antiarrhythmic drugs and beta-blockers; in patients with significant electrolyte imbalances. Ondansetron should be used with caution in patients with QTc prolongation or risk of QTc prolongation, including patients with electrolyte imbalances, congestive heart failure, bradyarrhythmias, or in patients taking other medications that may cause QT prolongation or electrolyte imbalances or decreased heart rate.

Side Effects

From the central nervous system: headache, dizziness, spontaneous movement disorders, convulsions.

From the cardiovascular system: chest pain (in some cases with ST segment depression), arrhythmias, arterial hypotension, bradycardia.

From the digestive system: hiccups, dry mouth, diarrhea, constipation, transient asymptomatic increase in transaminase activity in the blood serum.

Allergic reactions: urticaria, bronchospasm, laryngospasm, angioedema, anaphylaxis.

Local reactions: pain, burning, redness at the injection site.

Other: flushing of the face, feeling of heat, temporary impairment of visual acuity, hypokalemia.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf life

2 years

Manufacturer

Lance Farm, Russia